Roche Holding AG is collaborating with Warp Drive Bio Inc. to discover and develop multiple antibiotics.
Under the collaboration, Warp Drive will deploy its proprietary Genome Mining Platform to advance multiple classes of antibiotics with activity against clinically important, drug-resistant, Gram-negative pathogens.
Roche will receive an option to acquire global license to develop and commercialize certain antibiotics developed under the collaboration.
Warp Drive will receive $87 million in up-front payment and will be eligible to receive up to $300 million in specific clinical, regulatory and sales milestones on products licensed to Roche. Warp Drive will also be eligible for royalties on future net sales.
Warp Drive is identifying and evaluating over 100 classes of potential antibiotics that were previously undiscovered and thus never analyzed for their impact on human health.